The Food and Drug Administration (FDA) endorses to the Bureau of Internal Revenue (BIR) the updated list of VAT-Exempt Medicines (as of March 2022) under RA 11354, otherwise known as the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act.
The Department of Health expressed elation over the signing of Executive Order (EO) No. 155, by President Rodrigo Roa Duterte adding 34 medicines to the list of drugs with mandatory price caps.
DOH informs the public of the adjustments in the Maximum Retail Price (MRP) of certain medicines that are covered by EO 155
Government-Mediated Access Price (GMAP) Adjustment of Co-Amoxiclav and Dutasteride Preparations Related Posts Maximum Retail Price of Drugs and Medicines 14 Sep 2020 (Executive Order #155) Further Improving Access to Healthcare continue reading : (Department Circular No. 2022-0046) Government-Mediated Access Price (GMAP) Adjustment of Co-Amoxiclav and Dutasteride Preparations
Generic Nomenclature of Amlodipine + Perindopril Products Under Executive Order No. 155 Related Posts Maximum Retail Price of Drugs and Medicines 14 Sep 2020 (Executive Order #155) Further Improving Access continue reading : (Department Circular No. 2022-0016) Generic Nomenclature of Amlodipine + Perindopril Products Under Executive Order No. 155
Department Circular 2021-0088 Related Posts Mark-up Regulation of Essential Medicines in DOH Facilities 07 Oct 2020 Drug Price Reference Index 07 Oct 2020 Maximum Retail Price of Drugs and Medicines continue reading : Government-Mediated Access Price (GMAP) Adjustment of Co-Amoxiclav Preparations
Related Posts Mark-up Regulation of Essential Medicines in DOH Facilities 07 Oct 2020 Drug Price Reference Index 07 Oct 2020 Maximum Retail Price of Drugs and Medicines 14 Sep 2020 continue reading : DOH, PhilHealth, DTI Sign JAO on Pricing Negotiations for Single-Sourced Health Commodities (Press Release)